protein tyrosine phosphatase non-receptor type 12Genealiases: PTP-PEST · PTPG1
Q-omics provides the consensus-scored PTPN12 profile across patient tissues and cancer cell-line models. PTPN12 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, PTPN12 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, PTPN12 protein abundance shows 32,557 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight CESC, HNSC, and GBM as cancer lineages where PTPN12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTPN12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTPN12 survival associations across molecular data types. PTPN12 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTPN12 RNA expression–survival associations across cancer types. High PTPN12 expression shows unfavorable associations in CESC, KIRP, ACC, LIHC and LGG, but favorable associations in KIRC. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for PTPN12 RNA expression.
This table summarizes PTPN12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 11. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PTPN12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTPN12 shows higher tumor expression in HNSC, KIRC, LIHC, COAD, KIRP and READ. The HNSC box plot shows higher PTPN12 RNA expression in tumor versus normal tissue (log2 FC = +1.849, t-test p < 0.001).
This table shows molecular features associated with PTPN12 in patient tissues and cancer cell lines. In patient samples, PTPN12 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PTPN12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and CNS.
